Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Gene Therapy in a Patient with Sickle Cell Disease
source: The New England Journal of Medicine
year: 2017
authors: Ribeil JA, Hacein-Bey-Abina S, Payen E, Magnani A, Semeraro M, Magrin E, Caccavelli L, Neven B, Bourget P, El Nemer W, Bartolucci P, Weber L, Puy H, Meritet JF, Grevent D, Beuzard Y, Chrétien S, Lefebvre T, Ross RW, Negre O1, Veres G, Sandler L, Soni S, de Montalembert M, Blanche S, Leboulch P, Cavazzana M
summary/abstract:Sickle cell disease results from a homozygous missense mutation in the β-globin gene that causes polymerization of hemoglobin S. Gene therapy for patients with this disorder is complicated by the complex cellular abnormalities and challenges in achieving effective, persistent inhibition of polymerization of hemoglobin S. We describe our first patient treated with lentiviral vector-mediated addition of an antisickling β-globin gene into autologous hematopoietic stem cells. Adverse events were consistent with busulfan conditioning. Fifteen months after treatment, the level of therapeutic antisickling β-globin remained high (approximately 50% of β-like-globin chains) without recurrence of sickle crises and with correction of the biologic hallmarks of the disease.
DOI: 10.1056/NEJMoa1609677read more full text
Related Content
-
Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Effi...Background: Hydroxyurea prevents disea...
-
SCDAA Gene Therapy Town Hall – Webinarhttps://www.youtube.com/watch?v=J77Gq9yI...
-
Megan Davis, MDDr. Megan Davis received her medical deg...
-
Chronic Opioid Use Pattern in Adult Patients with Sickle Cell DiseaseBackground: Pain, the hallmark complicat...
-
Sickle Cell Anemia Toddlers Benefit from Maximal Hydroxyurea Doses, Study FindsIntensifying treatment with hydroxyurea ...
-
Gene Therapy: Your Questions Answeredhttps://www.youtube.com/watch?v=5ChXI6cS...
-
ASH offers early look at updated SCD guidelines: Experts formulated >50 recommendations on sickle cell diseaseThe American Society of Hemato...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.